Xellia Pharmaceuticals

Copenhagen, Denmark Founded: 1903 • Age: 123 yrs Acquired By Novo Holdings
Manufacturer of active pharmaceutical ingredients and finished dosage forms

About Xellia Pharmaceuticals

Xellia Pharmaceuticals is a Healthcare company based in Copenhagen (Denmark) founded in 1903, and was acquired by Novo Holdings in May 2013. Manufacturer of active pharmaceutical ingredients and finished dosage forms. The company has 52 employees. Its Indian entity Xellia Pharmaceuticals Private Limited reported revenue of β‚Ή28.32 Cr. Its focus areas include Traditional Pharmaceuticals, Generics and Diversified.

Company details

Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals operates in the pharmaceutical sector with a focus on anti-infective therapies. Active pharmaceutical ingredients are supplied to companies worldwide, while finished dosage forms are provided mainly through contract manufacturing organizations. Research and development, manufacturing, and commercialization activities are conducted, with emphasis placed on sustainable practices for critical care treatments of serious infections.

Key Metrics
  • Indian entity revenue
    ₹28.32 Cr

    FY 2025 · +16% YoY

  • Indian entity net profit
    ₹2.28 Cr

    FY 2025 · 8% margin

  • Indian entity EBITDA
    ₹3.71 Cr

    FY 2025 · 13% margin

  • Investors
  • Employee Count
    52
  • Acquired by
    Novo Holdings

    (May 2013)

Investors in Xellia Pharmaceuticals

Xellia Pharmaceuticals has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Novo Holdings.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Private equity and venture capital fund focused on the healthcare sector
novoholdings.dkHellerup, Denmark
Premium access

Investor details for Xellia Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Xellia Pharmaceuticals Private Limited (Xellia Pharmaceuticals)

Xellia Pharmaceuticals Private Limited is the primary company behind Xellia Pharmaceuticals. The board of Xellia Pharmaceuticals Private Limited currently have 4 directors; the longest-serving is Soren Hostrup, appointed in 2024. 8 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Soren Hostrup
DIN 10724148
Director20 Aug 20242 yrs 2 moXellia Pharmaceuticals Private Limited
Kasi Visweswara Venkata Satya Lakshmi Nagakishore Sripada
DIN 11416360
Additional Director16 Dec 202511 moXellia Pharmaceuticals Private Limited
Eva Blem
DIN 11469480
Additional Director12 Jan 202610 moXellia Pharmaceuticals Private Limited
Per Bork Eppers
DIN 11469479
Additional Director12 Jan 202610 moXellia Pharmaceuticals Private Limited

People of Xellia Pharmaceuticals

92 people are tracked at Xellia Pharmaceuticals (37 in leadership, 5 in board & advisors, 50 in team); the tracked headcount is 52.

NameRoleGroup
Anders Dorph
Senior Director, Global Supply ChainLeadership
Rahul Chhawsaria
Associate Director Global Supply ChainLeadership
Aurélien Grosso
Senior Director Global Supply ChainLeadership
Josef Christensen
Director, Strategy & Commercial TransformationLeadership
Ken Ruggiero
Head Of Facilities ManagementLeadership
Vicente Oller Más
CFOLeadership
Norbert Denes
Head Of Finance Hungary & CroatiaLeadership
Vidya Viswanathan
Director, India Finance, Admin & HR And Global Fp&aLeadership
Jeppe Palm Beckmann
Director - Head Of Transformation, Global Product Supply & QualityLeadership
Anne Mette Nygard
Director Strategic ProgramsLeadership
Site Director IndiaLeadership
Florian Falch
Chief People & Culture OfficerLeadership
Michael Kocher
CEOLeadership
Alexander Sproedt
Chief Strategy & Transformation OfficerLeadership
Gael Bernard
Chief Commercial Officer - Executive Vice PresidentLeadership
Dan Gnolfo
Vice President Of Finance, North AmericaLeadership
Eva Farkas
Managing Director (quality)Leadership
Peter Baker
Chief Commercial OfficerLeadership
Doug Knutson
Director, Commercial Finance & Sales EffectivenessLeadership
Søren Hostrup
Chief Legal Officer - Executive Vice PresidentLeadership

72 more people are available in the full profile.

Premium access

Complete people profiles for Xellia Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Financials of Xellia Pharmaceuticals

Figures of Xellia Pharmaceuticals Private Limited, the primary company behind Xellia Pharmaceuticals, for FY 2025. Revenue was ₹28.32 Cr (+16% year on year). Net profit was ₹2.28 Cr (8% margin). EBITDA was ₹3.71 Cr (13% margin). Revenue has grown at a compounded annual rate of +16% over three years and +12% over five years.

  • ₹28.32 CrRevenue · FY 2025 · +16% YoY
  • ₹2.28 CrNet profit · 8% margin
  • ₹3.71 CrEBITDA · 13% margin
  • ₹1 LakhPaid-up capital
  • 52Employees (provident fund records)
  • +16%Revenue CAGR, 3 years
  • +12%Revenue CAGR, 5 years

Balance sheet, profit and loss, cash flow and ratios of Xellia Pharmaceuticals Private Limited are on its company page.

Premium access

Detailed financial statements for Xellia Pharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of Xellia Pharmaceuticals

2 dated milestones of Xellia Pharmaceuticals across 110 years, from founding to its latest funding, stage changes and deals.

  1. Founded Xellia Pharmaceuticals is founded.
  2. Exit Acquired by Novo Holdings.

Web traffic of Xellia Pharmaceuticals

The website of Xellia Pharmaceuticals (xellia.com) receives about 6.5K visits a month and ranks #3,179,039 among all websites worldwide, #4,186 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    6.5K
  • Unique visitors
    2.7K

    per month

  • Global rank
    #3,179,039

    among all websites

  • Category rank
    #4,186

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Xellia Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
lundbeck.com
100%
137.6K#280,857View details
contractpharma.com
100%
67.7K#631,663View details
empr.com
empr.com
60%
#153,602–
mims.com
mims.com
60%
#27,323–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Frequently Asked Questions about Xellia Pharmaceuticals

Xellia Pharmaceuticals was founded in 1903.

Xellia Pharmaceuticals is headquartered in Copenhagen, Denmark.

Xellia Pharmaceuticals has 52 employees.

The primary company behind Xellia Pharmaceuticals, Xellia Pharmaceuticals Private Limited, reported revenue of β‚Ή28.32 Cr for FY 2025, up 16% year on year.

Founded in 1903 and headquartered in Copenhagen, Denmark, Xellia Pharmaceuticals operates in the pharmaceutical sector with a focus on anti-infective therapies. Active pharmaceutical ingredients are supplied to companies worldwide, while finished dosage forms are provided mainly through contract manufacturing organizations. Research and development, manufacturing, and commercialization activities are conducted, with emphasis placed on sustainable practices for critical care treatments of serious infections.

Xellia Pharmaceuticals has 1 investor. Key investors include Novo Holdings.

Xellia Pharmaceuticals operates through Xellia Pharmaceuticals Private Limited.

Yes. Xellia Pharmaceuticals was acquired by Novo Holdings in May 2013.

The legal entities of Xellia Pharmaceuticals currently have 4 directors, including Soren Hostrup, Eva Blem, Per Bork Eppers and others.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available